Related Experiment Video

Updated: Aug 4, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K

RUNX2 Reverses p53-Induced Chemotherapy Resistance in Gastric Cancer

Yuan Huang1, Lu Liang2, Yong-Xiang Zhao3

  • 1Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, People's Republic of China.

Pharmacogenomics and Personalized Medicine
|April 3, 2023
PubMed
Abstract

Insights

Runt-related transcription factor 2 (RUNX2) is highly expressed in chemotherapy-resistant gastric cancer. Silencing RUNX2 can reverse resistance by regulating the p53 apoptosis pathway, suggesting RUNX2 as a therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Gastric cancer remains a leading cause of cancer mortality globally.
  • Chemoresistance significantly hinders treatment efficacy in gastric cancer patients.
  • Understanding resistance mechanisms is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the role of runt-related transcription factor 2 (RUNX2) in platinum-based chemotherapy resistance in gastric cancer.
  • To elucidate the underlying molecular mechanisms by which RUNX2 influences chemoresistance.
  • To evaluate RUNX2 as a potential biomarker for chemotherapy resistance.

Main Methods:

  • Establishment of a drug-resistant gastric cancer cell model.
  • Exogenous silencing of RUNX2 to assess its impact on drug resistance.
  • Analysis of RUNX2 expression levels in patient tumor samples and correlation with clinical outcomes.

Main Results:

  • RUNX2 was significantly upregulated in drug-resistant gastric cancer cells and tissues.
  • Exogenous silencing of RUNX2 reversed chemoresistance in gastric cancer models.
  • RUNX2 was found to negatively regulate the p53 apoptosis pathway, diminishing chemotherapeutic effects.

Conclusions:

  • RUNX2 plays a critical role in mediating platinum-based chemotherapy resistance in gastric cancer.
  • RUNX2 represents a potential therapeutic target for overcoming chemoresistance.
  • Further research into RUNX2 inhibition may lead to improved gastric cancer treatment strategies.
Keywords:
RUNX2chemotherapy resistancegastric cancerplatinum

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K
Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

12.8K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K